BioSpace News Archive

Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form.

Stereotaxis today announced it will host an inaugural Innovation Day by live webcast on December 13.

Pliant Therapeutics, Inc. today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer will participate in virtual fireside chats at the following investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference – Pliant’s pre-recorded fireside chat will be available on Monday, November 22, 2021, at 10:00am ET.

Tempest Therapeutics, Inc. today announced the first patient has been dosed with TPST-1495 in combination with pembrolizumab in the Phase 1a/1b open-label, dose and schedule optimization study of TPST-1495 in patients with solid tumors.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today released positive interim data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the first-in-man Phase 1 ReSPECT™-GBM clinical trial in patients with recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from two scientific posters for its Phase 2 clinical studies of VAL-083, the Company’s lead compound for the treatment of glioblastoma multiforme (GBM).

Elevation Oncology, Inc. today announced that members of the senior management team will present a corporate overview and participate in one-on-one investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place November 29, 2021 to December 2, 2021.

Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease, announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and as a member of the company’s executive team.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global TROPION-Breast01 phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).

BAKX Therapeutics announced it closed $25 million in a Series A fundraising led by AB Magnitude Ventures Group with Ipsen Pharma SA and Sherpa Healthcare Partners.